Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer (KEYNOTE166)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02448303
Recruitment Status : Unknown
Verified November 2016 by Acerta Pharma BV.
Recruitment status was:  Active, not recruiting
First Posted : May 19, 2015
Last Update Posted : December 1, 2016
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : June 2017
  Estimated Study Completion Date : December 2017